Want to see BSEM full AI Analyst Report?
BSEM Stock Chart & Stats
$3.81
$0.18(4.59%)
At close: 4:00 PM EDT
$3.81
$0.18(4.59%)
Day’s Range― - ―
52-Week Range$2.25 - $8.40
Previous CloseN/A
Volume31.76K
Average Volume (3M)145.37K
Market Cap
$68.30M
Enterprise Value$51.44
Total Cash (Recent Filing)$6.96M
Total Debt (Recent Filing)$1.22M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Nov 17, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding17,832,811
10 Day Avg. Volume216,562
30 Day Avg. Volume145,368
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.63
Price to Sales (P/S)1.34
P/FCF Ratio9.67
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.00Price Target Upside83.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.95
Revenue Forecast (FY)$29.00M
Bulls Say, Bears Say
Bulls Say
Hospital Revenue GrowthHospital revenue is expanding in the company’s targeted care setting, supporting a more focused commercial model and demonstrating customer adoption. Continued hospital growth, combined with a larger sales organization, could provide a durable foundation for revenue expansion over the next several quarters.
Raised Revenue OutlookThe higher revenue outlook indicates management sees sufficient commercial momentum to raise its minimum 2026 target. Sequential growth, increasing sales capacity, and hospital traction may improve operating leverage if execution continues and the company converts its expanded commercial footprint into recurring product demand.
Conservative Recent LeverageLow recent leverage and positive equity provide a stronger financial base than the company had in prior years, reducing the immediate burden of debt service. This balance-sheet position can preserve flexibility for working capital and strategic investment, even though profitability remains inconsistent.
Bears Say
Unstable ProfitabilityThe sharp swing from strong 2024 profitability to later losses shows that earnings power has not yet been demonstrated consistently. Deep TTM losses and negative revenue and gross profit materially increase uncertainty about the durability of margins and the timing of sustainable operating profitability.
Cash Burn And Contingent PaymentRecent cash consumption is significant relative to the reported cash balance, while the pending contingent payment creates an additional funding requirement. If operating losses and cash use persist, BioStem may need further financing or payment arrangements, limiting flexibility to fund commercial expansion internally.
Equity Dilution RiskThe financing improves near-term working-capital access but increases the potential share count through both issued stock and warrants. Repeated reliance on equity capital can dilute existing holders and signals that internal cash generation may not yet be sufficient to support obligations and growth investments.
BioStem Technologies News
BSEM FAQ
What was BioStem Technologies Inc’s price range in the past 12 months?
BioStem Technologies Inc lowest stock price was $2.25 and its highest was $8.40 in the past 12 months.
What is BioStem Technologies Inc’s market cap?
BioStem Technologies Inc’s market cap is $68.30M.
When is BioStem Technologies Inc’s upcoming earnings report date?
BioStem Technologies Inc’s upcoming earnings report date is Nov 17, 2026 which is in 46 days.
How were BioStem Technologies Inc’s earnings last quarter?
BioStem Technologies Inc released its earnings results on Aug 12, 2026. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.5 by -$0.02.
Is BioStem Technologies Inc overvalued?
According to Wall Street analysts BioStem Technologies Inc’s price is currently Undervalued.
Does BioStem Technologies Inc pay dividends?
BioStem Technologies Inc does not currently pay dividends.
What is BioStem Technologies Inc’s EPS estimate?
BioStem Technologies Inc’s EPS estimate is -0.43.
How many shares outstanding does BioStem Technologies Inc have?
BioStem Technologies Inc has 17,832,811 shares outstanding.
What happened to BioStem Technologies Inc’s price movement after its last earnings report?
BioStem Technologies Inc reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.5. Following the earnings report the stock price went down -18.421%.
Which hedge fund is a major shareholder of BioStem Technologies Inc?
Currently, no hedge funds are holding shares in BSEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioStem Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (83.73% Upside)
$7.00 (83.73% Upside)
Blogger Sentiment
Bullish
BSEM Sentiment 100%
Sector Average 65%
Sector Average 65%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-56.65%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
BioStem Technologies Inc
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
BSEM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights strong operating execution around integration, commercial expansion, product and IP progress, sequential revenue growth (+29.5% quarter-over-quarter) and a raised revenue outlook. However, meaningful near-term financial challenges were emphasized: a $9.0 million GAAP loss, adjusted EBITDA loss, cash down to $7.0 million (≈49% decline sequentially), a $10 million contingent payment pending, and anticipated H2 margin pressure tied to legacy inventory. Management is progressing on strategic initiatives (Nasdaq uplisting, CRM/ERP integration, salesforce scale, patents, clinical data and a planned manufacturing transfer), but near-term liquidity and profitability depend on executing financing plans and the 2027 manufacturing transfer. Overall, positive operational momentum is balanced by significant near-term financial and execution risks.View all BSEM earnings summariesBSEM Stock 12 Month Forecast
Average Price Target
$7.00
▲(83.73% Upside)